Share on StockTwits

Neuralstem (NYSE:CUR) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 9,611,785 shares, an increase of 34.3% from the June 30th total of 7,156,010 shares, AnalystRatings.NET reports. Based on an average daily volume of 975,361 shares, the short-interest ratio is presently 9.9 days. Approximately 11.6% of the shares of the stock are short sold.

CUR has been the subject of a number of recent research reports. Analysts at Zacks reiterated an “outperform” rating on shares of Neuralstem in a research note on Wednesday, June 25th. They now have a $7.00 price target on the stock. Separately, analysts at Aegis raised their price target on shares of Neuralstem from $6.00 to $7.00 in a research note on Wednesday, June 25th. They now have a “buy” rating on the stock. Finally, analysts at Aegis raised their price target on shares of Neuralstem to $6.00 in a research note on Tuesday, May 27th.

Neuralstem (NYSE:CUR) traded down 2.11% on Thursday, hitting $3.25. The stock had a trading volume of 412,553 shares. Neuralstem has a 52 week low of $1.30 and a 52 week high of $4.81. The stock has a 50-day moving average of $3.91 and a 200-day moving average of $3.74. The company’s market cap is $282.0 million.

Neuralstem (NYSE:CUR) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.07) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.06) by $0.01. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.35 million. On average, analysts predict that Neuralstem will post $-0.25 earnings per share for the current fiscal year.

Neuralstem, Inc is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.